Wiesner Christoph, Jakse Gerhard, Rohde Detlef
Department of Urology, Medical Faculty, University of Aachen, Aachen, Germany.
Oncol Rep. 2002 Jan-Feb;9(1):189-92.
Local recurrence (LR) of renal cell carcinoma (RCC) after nephrectomy is a rare event with a poor prognosis. The clinical outcome of 15 patients with LR after tumor nephrectomy was analyzed retrospectively. Within a mean follow-up of 28 months (1-110 months) the mean time to recurrence (TTLR) was 23 months. Mean time to further tumor progression (TTP) after surgery was 22.2 months (11-32 months), after surgery and adjunctive therapy 6.8 months (3-15 months+) and after chemoimmunotherapy alone 3.6 months (3-6 months). Tumor specific survival (TSS) rate was 47% at 1 year and 33% at 3 years. Mean TSS after surgery was 62.2 months (38-110 months), after resection and adjunctive treatment 26 months (8-74 months) and after chemoimmunotherapy 9.2 months (7-15 months). In conclusion, surgery is recommended for treatment of LR. Additional benefit is not confirmed for any adjuctive therapy.
肾切除术后肾细胞癌（RCC）的局部复发（LR）是一种罕见事件，预后较差。对15例肿瘤肾切除术后发生LR的患者的临床结局进行了回顾性分析。在平均28个月（1 - 110个月）的随访期内，平均复发时间（TTLR）为23个月。术后至肿瘤进一步进展（TTP）的平均时间为22.2个月（11 - 32个月），术后联合辅助治疗后为6.8个月（3 - 15个月以上），单纯化疗免疫治疗后为3.6个月（3 - 6个月）。1年时的肿瘤特异性生存率（TSS）为47%，3年时为33%。术后平均TSS为62.2个月（38 - 110个月），切除及辅助治疗后为26个月（8 - 74个月），化疗免疫治疗后为9.2个月（7 - 15个月）。总之，建议手术治疗LR。未证实任何辅助治疗有额外益处。
